Brachytherapy Unit, Gustave Roussy Cancer Campus, Villejuif, France; Radiotherapy Department, Gustave Roussy, Villejuif, France.
Brachytherapy Unit, Gustave Roussy Cancer Campus, Villejuif, France; Radiotherapy Department, Gustave Roussy, Villejuif, France; Radiotherapy Department, Oscar Lambret Comprehensive Cancer Center, Lille, France.
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):411-420. doi: 10.1016/j.ijrobp.2018.02.004. Epub 2018 Feb 13.
To study correlations between dose-volume parameters of the whole bladder and bladder trigone and late urinary toxicity in locally advanced cervical cancer patients treated with pulsed-dose-rate brachytherapy.
Patients with locally advanced cervical cancer treated with chemoradiation therapy and pulsed-dose-rate brachytherapy from 2004 to 2015 were included. Cumulative dose-volume parameters of the whole bladder and bladder trigone were converted into 2-Gy/fraction equivalents (EQD2, with α/β = 3 Gy); these parameters, as well as clinical factors, were analyzed as predictors of toxicity in patients without local relapse.
A total of 297 patients fulfilled the inclusion criteria. The median follow-up period was 4.9 years (95% confidence interval 4.5-5.3 years). In patients without local relapse (n = 251), the Kaplan-Meier estimated grade 2 or higher urinary toxicity rates at 3 years and 5 years were 25.4% and 32.1%, respectively. Minimal dose to the most exposed 2 cm of the whole bladder [Formula: see text] , bladder International Commission on Radiation Units & Measurements (ICRU) (B) dose, and trigone dose-volume parameters correlated with grade 2 or higher toxicity. At 3 years, the cumulative incidence of grade 2 or higher complications was 22.8% (standard error, 2.9%) for bladder [Formula: see text] < 80 Gy versus 61.8% (standard error, 12.7%) for [Formula: see text] ≥ 80 Gy (P = .001). In the subgroup of patients with bladder [Formula: see text] ≤ 80 Gy, a trigone dose delivered to 50% of the volume (D) > 60 Gy was significant for grade 2 or higher toxicity (P = .027). The probability of grade 3 or higher toxicities increased with bladder [Formula: see text] > 80 Gy (16.7% vs 1.6%; hazard ratio [HR], 5.77; P = .039), B dose > 65 Gy (4.9% vs 1.3%; HR, 6.36; P = .018), and trigone D > 60 Gy (3.1% vs 1.2%; HR, 6.29; P = .028). Pearson correlation coefficients showed a moderate correlation between bladder [Formula: see text] , B dose, and bladder trigone D (P < .0001).
These data suggest that [Formula: see text] ≤ 80 Gy should be advised for minimizing the risk of severe urinary complications (<15%). Bladder trigone dose was also predictive of severe late urinary toxicity. These constraints need further confirmation in a multicenter prospective setting.
研究局部晚期宫颈癌患者接受脉冲剂量率近距离放射治疗后,全膀胱和膀胱三角剂量-体积参数与晚期尿毒性之间的相关性。
纳入 2004 年至 2015 年接受放化疗和脉冲剂量率近距离放射治疗的局部晚期宫颈癌患者。将全膀胱和膀胱三角的累积剂量-体积参数转换为 2-Gy/fraction 等效物(EQD2,α/β=3 Gy);分析这些参数以及临床因素作为无局部复发患者毒性的预测因子。
共有 297 例患者符合纳入标准。中位随访时间为 4.9 年(95%置信区间 4.5-5.3 年)。在无局部复发的患者(n=251)中,3 年和 5 年的 Kaplan-Meier 估计的 2 级或更高级别的尿毒性发生率分别为 25.4%和 32.1%。全膀胱最小剂量至最暴露的 2cm[公式:见文本]、膀胱国际辐射单位和测量委员会(ICRU)(B)剂量和三角剂量-体积参数与 2 级或更高级别的毒性相关。在 3 年时,膀胱[公式:见文本]<80Gy 的累积发生率为 22.8%(标准误差,2.9%),而膀胱[公式:见文本]≥80Gy 的累积发生率为 61.8%(标准误差,12.7%)(P=.001)。在膀胱[公式:见文本]≤80Gy 的患者亚组中,三角剂量至 50%体积(D)>60Gy 与 2 级或更高级别的毒性显著相关(P=.027)。随着膀胱[公式:见文本]>80Gy(16.7% vs 1.6%;风险比[HR],5.77;P=.039)、B 剂量>65Gy(4.9% vs 1.3%;HR,6.36;P=.018)和三角 D>60Gy(3.1% vs 1.2%;HR,6.29;P=.028),发生 3 级或更高级别的毒性的概率增加。Pearson 相关系数显示膀胱[公式:见文本]、B 剂量和膀胱三角 D 之间存在中度相关性(P<.0001)。
这些数据表明,建议膀胱[公式:见文本]≤80Gy 以最大程度降低严重尿并发症的风险(<15%)。膀胱三角剂量也可预测晚期严重尿毒性。这些限制需要在多中心前瞻性研究中进一步证实。